Cyramza and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Cyramza (ramucirumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Alimta, and have Gastric cancer.

The phase IV clinical study analyzes which people have Weakness when taking Cyramza. It is created by eHealthMe based on reports of 4,051 people who have side effects when taking Cyramza from the FDA, and is updated regularly.

What is Cyramza?

Cyramza has active ingredients of ramucirumab. eHealthMe is studying from 4,052 Cyramza users. Check the latest studies of Cyramza.

What is Weakness?

Weakness is found to be associated with 3,640 drugs and 6,613 conditions by eHealthMe. Check the latest studies of Weakness.

On Jul, 23, 2026

4,051 people reported to have side effects when taking Cyramza.
Among them, 46 people (1.14%) have Weakness.

Among these 46 people:

How long have people been on Cyramza when they have Weakness? *

What is the gender of people who have Weakness when taking Cyramza? *

female: 46.51 %
male: 53.49 %

What is the age of people who have Weakness when taking Cyramza? *

What are other drugs people take besides Cyramza? *

What are other side effects people have besides Weakness? *

Nausea (feeling of having an urge to vomit): 10 people, 21.74%
Mucosal Inflammation (infection of mucous membrane): 8 people, 17.39%
Dyspnea (difficult or laboured breathing): 8 people, 17.39%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 7 people, 15.22%
Abdominal Pain: 7 people, 15.22%
Neuropathy Peripheral (surface nerve damage): 6 people, 13.04%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 6 people, 13.04%
Malignant Neoplasm Progression (cancer tumour came back): 6 people, 13.04%
Fatigue (feeling of tiredness): 5 people, 10.87%
Diarrhea: 4 people, 8.70%

What are the existing conditions these people have? *

Gastric Cancer (stomach cancer): 20 people, 43.48%
Metastatic Gastric Cancer (cancer types can spread to the stomach from other place): 2 people, 4.35%
Oesophageal Adenocarcinoma (a cancer tumour of an epithelium in oesophagus): 2 people, 4.35%
Lung Cancer - Non-Small Cell (lung cancer): 2 people, 4.35%
Lung Carcinoma Cell Type Unspecified Stage Iv (the lung cancer has spread to other organs of the body, such as the other lung, brain, or liver): 2 people, 4.35%
Lung Neoplasm Malignant (cancer tumour of lung): 2 people, 4.35%
Nausea (feeling of having an urge to vomit): 2 people, 4.35%
Oedema (fluid collection in tissue): 2 people, 4.35%
Abdominal Pain: 2 people, 4.35%
Pain: 2 people, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Cyramza and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cyramza:

Cyramza (4,052 reports)

Weakness treatments and more:

Weakness (586,876 reports)

Browse all side effects of Cyramza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,640 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,613 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ramucirumab (the active ingredients of Cyramza) and Cyramza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.